Trials / Not Yet Recruiting
Not Yet RecruitingNCT07462182
Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction
Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction With Oligohydramnios.
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- Sponsor
- Muhammad Aamir Latif · Academic / Other
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
The local literature lacks comprehensive information regarding the actual incidence of intrauterine growth restriction (IUGR) and oligohydramnios and currently available therapeutic options. Therefore, the current study was planned with the objective to evaluate the impact of enoxaparin therapy compared with standard management on neonatal outcomes in pregnancies complicated by intrauterine growth restriction (IUGR) with oligohydramnios.
Detailed description
The use of enoxaparin is not yet a standard practice in pregnancies with IUGR and oligohydramnios without overt maternal thrombophilia. Given the notable incidence of IUGR and oligohydramnios and the limited therapeutic options currently available, exploring the potential benefits of enoxaparin therapy against standard management is both clinically and socially relevant. By investigating whether enoxaparin can improve fetal outcomes in this high-risk group, the findings of this study would generate evidence that could inform future management protocols, reduce preventable perinatal morbidity and mortality, and ultimately improve neonatal survival and health in Pakistan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enoxaparin | Patients will receive standard management plus enoxaparin 40 mg subcutaneously once daily until delivery |
| OTHER | Standard Management | Patients will continue with standard management alone. |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
- First posted
- 2026-03-10
- Last updated
- 2026-03-10
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT07462182. Inclusion in this directory is not an endorsement.